Anzeige
Mehr »
Login
Donnerstag, 21.11.2024 Börsentäglich über 12.000 News von 677 internationalen Medien
Von Solarenergie zu digitalen Assets: Die Strategie hinter der 75-Prozent-Rallye
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
247 Leser
Artikel bewerten:
(0)

Life Care Medical Devices Limited Completes Share Exchange with Health In Harmony Inc.

Finanznachrichten News

NEW YORK, March 29, 2013 /PRNewswire/ -- Life Care Medical Devices Limited ("LCMD Hong Kong"), a development stage medical device company developing and commercializing its Keyhole Cup device for use in laparoscopic surgery and its EPIOS Pain Management System, is pleased to announce the closing of its share exchange and reorganization with Health In Harmony Inc., a Nevada corporation (OTCQB: HTHH). Following the share exchange and reorganization, LCMD Hong Kong became a wholly-owned subsidiary of Health In Harmony. Furthermore, Health In Harmony changed its name to Life Care Medical Devices Limited ("LCMD Nevada"), and its shares will continue to be listed on the OTC QB market.In connection with the share exchange and reorganization, LCMD Nevada appointed two new directors, to be effective April 12, 2013.

As part of the terms of the share exchange and reorganization, LCMD Hong Kong's stockholders exchanged all of their beneficially owned shares of LCMD Hong Kong common stock for an aggregate of 29,200,000 shares of common stock of LCMD Nevada, which constitutes approximately 83.4% of the issued and outstanding common stock of LCMD Nevada post-closing. Details of the share exchange transaction can be found in LCMD Nevada's Current Report on Form 8-K to be filed with the United States Securities and Exchange Commission(the "SEC").

Following the share exchange and reorganization, the directors of LCMD Nevada include existing director Nickolay V. Kukekov, Ph.D, and directors-elect Glenn Foley and Arthur Malvett. Furthermore, Mr. Foley has been appointed Chief Executive Officer of LCMD Nevada and Mr. Malvett has been appointed Chief Operating Officer of LCMD Nevada. Details on the appointments can be found in the Information Statement expected to be filed with the SEC on April 1, 2013.

About Life Care Medical Devices Limited
Life Care Medical Devices Limited is a development stage medical device company developing and commercializing its Keyhole Cup device for use in laparoscopic surgery and its EPIOS Pain Management System. The Keyhole Cup is a proprietary, patent-in-process protected device for use in laparoscopic surgery. The EPIOS Pain Management System, its second product in development, is designed to address pain management without drugs or hardware devices, as a low cost, disposable product.

For more information visit: www.lifecmed.com

Safe Harbor
This release may contain certain forward-looking statements regarding our prospective performance and strategies within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995, and are including this statement for purposes of said safe harbor provisions.

Forward-looking statements, which are based on certain assumptions and describe future plans, strategies, and expectations of our company, are generally identified by use of words "anticipate," "believe," "estimate," "expect," "intend," "plan," "project," "seek," "strive," "try," or future or conditional verbs such as "could," "may," "should," "will," "would," or similar expressions. Our ability to predict results or the actual effects of our plans or strategies is inherently uncertain. Accordingly, actual results may differ materially from anticipated results. Some of the factors that could cause our actual results to differ from its expectations or beliefs include, without limitation, the risks discussed from time to time in our filings with the Securities and Exchange Commission.

Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. Except as required by applicable law or regulation, we undertake no obligation to update these forward-looking statements to reflect events or circumstances that occur after the date on which such statements were made.

SOURCE Life Care Medical Devices Limited

© 2013 PR Newswire
Nach Nvidia: 5 KI-Revolutionäre aus der zweiten Reihe!
Künstliche Intelligenz hat spätestens nach dem Raketenstart von Chat GPT das Leben aller verändert. Doch der Superzyklus steht nach Meinungen von Experten erst am Anfang. Während Aktien wie Nvidia von der ersten Aufwärtsentwicklung stark profitieren konnten, versprechen aussichtsreiche Player aus der

zweiten Reihe noch enormes Aufwärtspotenzial.

Im kostenlosen, exklusiven Spezialreport präsentieren wir ihnen 5 innovative KI-Unternehmen, die bahnbrechende Entwicklungen in diesem Sektor prägen könnten.

Warum sollten Sie dabei sein?
Trotz der jüngsten Erfolge steht die Entwicklung der künstlichen Intelligenz noch am Beginn eines neuen Superzyklus. Experten gehen davon aus, dass der Sektor bis 2032 global auf 1,3 Billionen US-Dollar explodieren wird, wobei ein großer Teil auf Hardware und Infrastruktur entfallen wird.

Nutzen Sie die Chance!
Fordern Sie sofort unseren brandneuen Spezialreport an und erfahren Sie, welche 5 KI-Aktien das größte Potenzial zur Vervielfachung besitzen. Dieser Report ist komplett kostenlos und zeigt Ihnen die aussichtsreichsten Investments im KI-Sektor.
Handeln Sie jetzt und sichern Sie sich Ihren kostenfreien Report!

Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.